Literature DB >> 15927895

Calcineurin inhibitor-induced nephrotoxicity and renal expression of P-glycoprotein.

Melanie S Joy1, Volker Nickeleit, Susan L Hogan, Bawana D Thompson, William F Finn.   

Abstract

STUDY
OBJECTIVE: To evaluate immunohistochemistry staining patterns for P-glycoprotein (P-gp) and a marker of early apoptosis (active caspase-3) in renal biopsy specimens obtained from solid organ transplant recipients with nephrotoxicity and those from a control group.
DESIGN: Retrospective analysis of pathology specimens and medical records.
SETTING: Medical university.
SUBJECTS: Twenty-nine solid organ transplant recipients with nephrotoxicity and 32 control patients.
MEASUREMENTS AND MAIN RESULTS: Medical records were reviewed for patient demographics, clinical laboratory results, and prescribed drugs. Immunohistochemistry techniques using primary antibodies to P-gp and active caspase-3 were performed to evaluate staining patterns of these proteins in the kidney specimens. Differences in measures of interest between groups were compared with the Fisher exact test for categoric data and Wilcoxon rank sum test for continuous data. Logistic and linear modeling were used to evaluate difference in measures of P-gp and active caspase-3 between groups while controlling for confounders. Immunohistochemistry confirmed the presence of P-gp in the renal tubules (apical and basal membranes and cytoplasm). Intensity of P-gp staining (score range 0-4) was reduced in renal specimens of transplant recipients with nephrotoxicity compared with the control specimens (mean +/- SD intensity scores 3.2 +/- 0.7 vs 3.8 +/- 0.4, p=0.0002). Neither P-gp-inducing nor P-gp-inhibiting drugs predicted expression of P-gp in the renal specimens of either group. The extent of tubular staining (score range 1-4) for the apoptosis marker, active caspase-3, was less in the nephrotoxicity group than in the control group (mean +/- SD extent scores 1.7 +/- 0.6 vs 2.8 +/- 0.5, p=0.0003).
CONCLUSION: P-glycoprotein expression was less pronounced in renal biopsy specimens with calcineurin inhibitor-induced nephrotoxicity compared with the nonnephrotoxic control specimens. Reduced P-gp expression was evident even when the analysis controlled for factors such as renal function, age, sex, race, diabetes mellitus, level of proteinuria, or prescribed therapy with P-gp inducers or inhibitors. Interpretation of the results from active caspase-3 staining requires further study.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15927895     DOI: 10.1592/phco.2005.25.6.779

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  15 in total

1.  Donor P-gp polymorphisms strongly influence renal function and graft loss in a cohort of renal transplant recipients on cyclosporine therapy in a long-term follow-up.

Authors:  J-B Woillard; J-P Rerolle; N Picard; A Rousseau; A Guillaudeau; E Munteanu; M Essig; M Drouet; Y Le Meur; P Marquet
Journal:  Clin Pharmacol Ther       Date:  2010-05-26       Impact factor: 6.875

Review 2.  Clinical implementation of pharmacogenetics in kidney transplantation: calcineurin inhibitors in the starting blocks.

Authors:  Laure Elens; Rachida Bouamar; Nauras Shuker; Dennis A Hesselink; Teun van Gelder; Ron H N van Schaik
Journal:  Br J Clin Pharmacol       Date:  2014-04       Impact factor: 4.335

3.  The POR rs1057868-rs2868177 GC-GT diplotype is associated with high tacrolimus concentrations in early post-renal transplant recipients.

Authors:  Shu Liu; Rong-Xin Chen; Jun Li; Yu Zhang; Xue-Ding Wang; Qian Fu; Ling-Yan Chen; Xiao-Man Liu; Hong-Bing Huang; Min Huang; Chang-Xi Wang; Jia-Li Li
Journal:  Acta Pharmacol Sin       Date:  2016-08-08       Impact factor: 6.150

Review 4.  Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part II.

Authors:  Christine E Staatz; Lucy K Goodman; Susan E Tett
Journal:  Clin Pharmacokinet       Date:  2010-04       Impact factor: 6.447

5.  Relationship between allograft cyclosporin concentrations and P-glycoprotein expression in the 1st month following renal transplantation.

Authors:  Benedetta C Sallustio; Benjamin D Noll; Janet K Coller; Jonathan Tuke; Graeme Russ; Andrew A Somogyi
Journal:  Br J Clin Pharmacol       Date:  2019-03-06       Impact factor: 4.335

Review 6.  Kidney Fibrosis: Origins and Interventions.

Authors:  Thomas Vanhove; Roel Goldschmeding; Dirk Kuypers
Journal:  Transplantation       Date:  2017-04       Impact factor: 4.939

7.  Donor ABCB1 variant associates with increased risk for kidney allograft failure.

Authors:  Jason Moore; Amy Jayne McKnight; Bernd Döhler; Matthew J Simmonds; Aisling E Courtney; Oliver J Brand; David Briggs; Simon Ball; Paul Cockwell; Christopher C Patterson; Alexander P Maxwell; Stephen C L Gough; Gerhard Opelz; Richard Borrows
Journal:  J Am Soc Nephrol       Date:  2012-10-11       Impact factor: 10.121

8.  Donor age and renal P-glycoprotein expression associate with chronic histological damage in renal allografts.

Authors:  Maarten Naesens; Evelyne Lerut; Hylke de Jonge; Boudewijn Van Damme; Yves Vanrenterghem; Dirk R J Kuypers
Journal:  J Am Soc Nephrol       Date:  2009-09-17       Impact factor: 10.121

Review 9.  The role of pharmacogenetics in the disposition of and response to tacrolimus in solid organ transplantation.

Authors:  Dennis A Hesselink; Rachida Bouamar; Laure Elens; Ron H N van Schaik; Teun van Gelder
Journal:  Clin Pharmacokinet       Date:  2014-02       Impact factor: 6.447

Review 10.  The role of genetics in drug dosing.

Authors:  Nicholas Ware
Journal:  Pediatr Nephrol       Date:  2012-02-23       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.